Telo Genomics Secures Option for Exclusive Global License on AI Technology to Detect Rare Malignant Cells
Telo Genomics Corp. has entered into a term sheet granting it an option to exclusively license an AI-based method for automated detection of low-frequency malignant cells. Developed jointly by the University of Manitoba and Technion Research and Development Foundation Ltd., this technology aims to improve liquid biops…